Biobanking and omics

Research output: Contribution to journalArticle

Abstract

Background: The “Era of Big Data” and “Precision Medicine” is now upon us. That is, interrogation of large data sets obtained from groups of similar patients or from the patient themselves over time will now hypothetically permit therapies to be designed to provide maximal efficacy with minimal side effects. However, such discoveries depend upon recruitment of very large numbers of subjects (tens of thousands) along with their associated biospecimens and medical records. When considering the establishment of a biobank or the refocusing of an existing repository for the purpose of “omics” research (i.e., genomics, metabolomics, proteomics, microbiomics, etc.) and/or precision medicine, there are a number of considerations to ponder. Each of these facets is discussed. Objective: The objective of this review is to describe best practices for the establishment and operations of a biobank that will be used for omics (genomics, proteomics, metabolomics, microbiomics) analyses based on published literature and our own practical experiences. Methods: We describe the most commonly described approaches to a variety of biobanking issues, including our own practical experiences over the past 5 years. Results: Based on the particular biobanking situation and downstream application, we have described best practices based on the literature and own experience, taking into consideration ease of application and costs. Conclusions: The banking of various types of clinical biospecimens has many valuable uses but often depends on overall costs versus sample utility. In addition, specimen flexibility is important but is influenced by the ease or difficulty of the application. It is always preferable to collect and stored a biospecimen in a format that allows for multiple types of downstream analyses, but that often requires additional expertise, equipment and reagents that can increase overall costs. We have described the methodologies most successfully applied to many situations.

Original languageEnglish (US)
JournalFrontiers in Biology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

proteomics
metabolomics
medicine
genomics
Precision Medicine
Metabolomics
Genomics
Practice Guidelines
Costs and Cost Analysis
banking
Proteomics
cost
repository
adverse effects
therapeutics
Medical Records
methodology
Equipment and Supplies
Research
sampling

Keywords

  • big data
  • biobanking
  • genomics
  • metabolomics
  • methodology
  • microbiomics
  • precision medicine

ASJC Scopus subject areas

  • Biotechnology
  • Ecology, Evolution, Behavior and Systematics
  • Ecology
  • Genetics

Cite this

Biobanking and omics. / Harris, David T.

In: Frontiers in Biology, 01.01.2018.

Research output: Contribution to journalArticle

@article{325c59727385433aa9e3e73ec973bfd6,
title = "Biobanking and omics",
abstract = "Background: The “Era of Big Data” and “Precision Medicine” is now upon us. That is, interrogation of large data sets obtained from groups of similar patients or from the patient themselves over time will now hypothetically permit therapies to be designed to provide maximal efficacy with minimal side effects. However, such discoveries depend upon recruitment of very large numbers of subjects (tens of thousands) along with their associated biospecimens and medical records. When considering the establishment of a biobank or the refocusing of an existing repository for the purpose of “omics” research (i.e., genomics, metabolomics, proteomics, microbiomics, etc.) and/or precision medicine, there are a number of considerations to ponder. Each of these facets is discussed. Objective: The objective of this review is to describe best practices for the establishment and operations of a biobank that will be used for omics (genomics, proteomics, metabolomics, microbiomics) analyses based on published literature and our own practical experiences. Methods: We describe the most commonly described approaches to a variety of biobanking issues, including our own practical experiences over the past 5 years. Results: Based on the particular biobanking situation and downstream application, we have described best practices based on the literature and own experience, taking into consideration ease of application and costs. Conclusions: The banking of various types of clinical biospecimens has many valuable uses but often depends on overall costs versus sample utility. In addition, specimen flexibility is important but is influenced by the ease or difficulty of the application. It is always preferable to collect and stored a biospecimen in a format that allows for multiple types of downstream analyses, but that often requires additional expertise, equipment and reagents that can increase overall costs. We have described the methodologies most successfully applied to many situations.",
keywords = "big data, biobanking, genomics, metabolomics, methodology, microbiomics, precision medicine",
author = "Harris, {David T.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s11515-018-1505-3",
language = "English (US)",
journal = "Frontiers in Biology",
issn = "1674-7984",
publisher = "Higher Education Press",

}

TY - JOUR

T1 - Biobanking and omics

AU - Harris, David T.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The “Era of Big Data” and “Precision Medicine” is now upon us. That is, interrogation of large data sets obtained from groups of similar patients or from the patient themselves over time will now hypothetically permit therapies to be designed to provide maximal efficacy with minimal side effects. However, such discoveries depend upon recruitment of very large numbers of subjects (tens of thousands) along with their associated biospecimens and medical records. When considering the establishment of a biobank or the refocusing of an existing repository for the purpose of “omics” research (i.e., genomics, metabolomics, proteomics, microbiomics, etc.) and/or precision medicine, there are a number of considerations to ponder. Each of these facets is discussed. Objective: The objective of this review is to describe best practices for the establishment and operations of a biobank that will be used for omics (genomics, proteomics, metabolomics, microbiomics) analyses based on published literature and our own practical experiences. Methods: We describe the most commonly described approaches to a variety of biobanking issues, including our own practical experiences over the past 5 years. Results: Based on the particular biobanking situation and downstream application, we have described best practices based on the literature and own experience, taking into consideration ease of application and costs. Conclusions: The banking of various types of clinical biospecimens has many valuable uses but often depends on overall costs versus sample utility. In addition, specimen flexibility is important but is influenced by the ease or difficulty of the application. It is always preferable to collect and stored a biospecimen in a format that allows for multiple types of downstream analyses, but that often requires additional expertise, equipment and reagents that can increase overall costs. We have described the methodologies most successfully applied to many situations.

AB - Background: The “Era of Big Data” and “Precision Medicine” is now upon us. That is, interrogation of large data sets obtained from groups of similar patients or from the patient themselves over time will now hypothetically permit therapies to be designed to provide maximal efficacy with minimal side effects. However, such discoveries depend upon recruitment of very large numbers of subjects (tens of thousands) along with their associated biospecimens and medical records. When considering the establishment of a biobank or the refocusing of an existing repository for the purpose of “omics” research (i.e., genomics, metabolomics, proteomics, microbiomics, etc.) and/or precision medicine, there are a number of considerations to ponder. Each of these facets is discussed. Objective: The objective of this review is to describe best practices for the establishment and operations of a biobank that will be used for omics (genomics, proteomics, metabolomics, microbiomics) analyses based on published literature and our own practical experiences. Methods: We describe the most commonly described approaches to a variety of biobanking issues, including our own practical experiences over the past 5 years. Results: Based on the particular biobanking situation and downstream application, we have described best practices based on the literature and own experience, taking into consideration ease of application and costs. Conclusions: The banking of various types of clinical biospecimens has many valuable uses but often depends on overall costs versus sample utility. In addition, specimen flexibility is important but is influenced by the ease or difficulty of the application. It is always preferable to collect and stored a biospecimen in a format that allows for multiple types of downstream analyses, but that often requires additional expertise, equipment and reagents that can increase overall costs. We have described the methodologies most successfully applied to many situations.

KW - big data

KW - biobanking

KW - genomics

KW - metabolomics

KW - methodology

KW - microbiomics

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85050220511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050220511&partnerID=8YFLogxK

U2 - 10.1007/s11515-018-1505-3

DO - 10.1007/s11515-018-1505-3

M3 - Article

JO - Frontiers in Biology

JF - Frontiers in Biology

SN - 1674-7984

ER -